Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …

Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …

Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …

Colorectal cancer is the third most common cancer in the world with increasing incidence
and mortality rates globally. Standard treatments for colorectal cancer have always been …

For many cancer types, the immune system plays an essential role in their development and
growth. Based on these rather novel insights, immunotherapeutic strategies have been …

Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …

Immunotherapy is a new and exciting modality of cancer treatments. Its role in
gastrointestinal malignancies has been promising, especially in advanced disease …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Background The majority of breast cancer patients die of metastasis rather than primary
tumors, whereas the molecular mechanisms orchestrating cancer metastasis remains poorly …

Gastrointestinal cancers (GICs) and neuroendocrine tumors (NETs) are often refractory to
therapy after metastasis. Adoptive cell therapy using chimeric antigen receptor (CAR) T …